IMAC HoldingsBACK Receivables Turnover is 0.00 as of Sep. 2025. The stock has 7 warning signs investors should review. Among 656 Healthcare Providers & Services companies, IMAC Holdings ranks worse than 98.78% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. IMAC Holdings's Revenue for the
three
months ended in Sep. 2025 was $0.02 Mil. IMAC Holdings's average Accounts Receivable for the
three
months ended in Sep. 2025 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
IMAC Holdings Receivables Turnover Related Terms
IMAC Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for IMAC Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BACK vs FCHS, NHLG, PAIYY: Receivables Turnover Comparison
For the Medical Care Facilities subindustry, IMAC Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IMAC Holdings Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where IMAC Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMAC Holdings (BACK) has a Receivables Turnover of 0.00 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IMAC Holdings and its competitors. According to the industry distribution chart, IMAC Holdings ranks #648 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 98.8%.
Is IMAC Holdings' Receivables Turnover too high?
IMAC Holdings' current Receivables Turnover is 0.00. Based on the distribution chart, IMAC Holdings ranks #648 out of 656 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does IMAC Holdings' Receivables Turnover compare to FCHS and NHLG?
According to the Healthcare Providers & Services industry distribution chart, IMAC Holdings ranks #648 out of 656 companies for Receivables Turnover. This places IMAC Holdings in the lower half of its industry. The industry median Receivables Turnover is 7.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.68, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IMAC Holdings and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IMAC Holdings's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For IMAC Holdings (BACK), the current Receivables Turnover is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BACK has been successfully added to your 